Evaluating CMR

Metabolic Syndrome and Type 2 Diabetes/CVD Risk

Comparison of Screening Tools

The Prospective Epidemiological Study of Myocardial Infarction

Page: Go to Previous Page 9 of 13 Go to Next Page

WHO, NCEP-ATP III, and IDF screening criteria were compared in another very large population-based study of 10,592 men 50 to 59 years of age from France and Belfast (Southern and Northern Europe) followed for 5 years (6). Entitled the prospective epidemiological study of myocardial infarction-étude PRospective de l’Infarctus du MyocardE (PRIME), it involved a nested case-control study cohort that matched 296 cases of coronary heart disease (CHD) to 540 CHD-free controls according to age, recruitment centre, and date. Metabolic syndrome prevalence was 36%, 30%, and 39% in cases and 29%, 23%, and 32% in controls according to WHO, NCEP-ATP III, and IDF clinical criteria, respectively. The corresponding ORs for future CHD were 1.40 (95% CI, 1.01-1.94), 1.46 (95% CI, 1.04-2.04), and 1.41 (95% CI, 1.02-1.95).


Reference
Previous Reference
Next Reference
6. Bataille V, Perret B, Dallongeville J, et al. Metabolic syndrome and coronary heart disease risk in a population-based study of middle-aged men from France and Northern Ireland. A nested case-control study from the PRIME cohort. Diabetes Metab 2006; 32: 475-9.